Freeze-thaw cycling raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-19 and is reviewed periodically as new material appears.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Carrey reunited with Joel Schumacher, director of Batman Forever, for The Number 23 (2007), a psychological thriller co-starring Virginia Madsen and Danny Huston. In the film, Carrey plays a man who becomes obsessed with the number 23, after finding a book about a man with the same obsession. The film was panned by critics. The following year Carrey provided his voice for Dr. Seuss' Horton Hears a Who! (2008). Carrey voiced Horton the Elephant for the CGI-animated feature, which was a box office success, grossing over $290 million worldwide. Carrey returned to live-action comedy, starring opposite Zooey Deschanel and Bradley Cooper in Yes Man (also 2008). Carrey played a man who signs up for a self-help program that teaches him to say yes to everything. Despite reviews being mixed, Rene Rodriquez of The Miami Herald stated, "Yes Man is fine as far as Jim Carrey comedies go, but it's even better as a love story that just happens to make you laugh." The film earned $225 million at the box office worldwide.
== See also == List of investigational antidepressants List of investigational generalized anxiety disorder drugs List of investigational post-traumatic stress disorder drugs List of investigational substance-related disorder drugs Corticotropin-releasing hormone antagonist
=== Deep brain stimulation === One treatment methodology that is very promising for the treatment of camptocormia is deep brain stimulation. Previously, deep brain stimulation and bilateral stimulation of the subthalamic nucleus and/or globus pallidus internus have been used to treat patients with Parkinson's disease. Studies have shown that similar treatments could be used on patients with severe camptocormia. By using the Burke-Fahn-Marsden Dystonia Rating Scale before and after treatment, it was found that patients experienced significant functional improvement in the ability to walk.
1993/2657) Private Legislation Procedure (Scotland) General Order 1993 (S.I. 1993/2660) European Communities (Designation) (No. 3) Order 1993 (S.I. 1993/2661) Birmingham City Council (Grand Union Canal Bridge) Scheme 1991 Confirmation Instrument 1993 (S.I. 1993/2662) European Convention on Extradition (Fiscal Offences) Order 1993 (S.I. 1993/2663) Admiralty Jurisdiction (Guernsey) Order 1993 (S.I. 1993/2664) Agriculture (Northern Ireland) Order 1993 (S.I. 1993/2665) Arms Control and Disarmament (Privileges and Immunities) Act 1988 (Guernsey) Order 1993 (S.I. 1993/2666) European Convention on Extradition (Hungary and Poland) (Amendment) Order 1993 (S.I. 1993/2667) Industrial Relations (Northern Ireland) Order 1993 (S.I. 1993/2668) Treaty on Open Skies (Privileges and Immunities) (Guernsey) Order 1993 (S.I. 1993/2669) Air Navigation (Fifth Amendment) Order 1993 (S.I. 1993/2670) Birmingham Heartlands Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2680) Croydon Community National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2681) Herefordshire Community Health National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2682) Princess Royal Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2683) Ravensbourne Priority Health National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2684) St. Helier National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I.
==== Breast cancer ==== The feasibility of 68Ga-Trivehexin PET imaging of breast cancer (BC) was demonstrated in a case of triple-negative BC. Another report suggested that 68Ga-Trivehexin PET/CT might offer superior detection efficacy for breast cancer compared to 18F-FDG PET/CT. Furthermore, in progesterone- and estrogen-receptor negative BC with elevated Ki67 proliferation index and strong E-cadherin, 68Ga-Trivehexin PET identified several 18F-FDG-avid lymph nodes as false positives. In a patient with lobular BC and pancreatic neuroendocrine tumor (PNET), 68Ga-Trivehexin selectively showed a PET signal only in the lobular carcinoma, while the metabolic tracer 18F-FGD and the neuroendocrine tumor tracer 68Ga-DOTATATE yielded PET signals for both the BC and PNET lesions.
Sources: en.wikipedia.org
== Sources == Tityus serrulatus, also known as the Brazilian yellow scorpion, is from the genus Tityus belonging to the family Buthidae. TsPep2 is identified from the venom of Tityus serrulatus by using a cDNA primer sequence based on the C-terminal amino acid sequence of KTx2 from Androctonus australis.
=== Development === Developmentally, the majority of mucous membranes are of endodermal origin. Exceptions include the palate, cheeks, floor of the mouth, gums, lips and the portion of the anal canal below the pectinate line, which are all ectodermal in origin.
==== During pregnancy ==== MDMA is a moderately teratogenic drug (i.e., it is toxic to the fetus). In utero exposure to MDMA is associated with a neuro- and cardiotoxicity and impaired motor functioning. Motor delays may be temporary during infancy or long-term. The severity of these developmental delays increases with heavier MDMA use. MDMA has been shown to promote the survival of fetal dopaminergic neurons in culture.
=== Solubility === Bronopol is readily soluble in water; the dissolution process is endothermic. Solutions containing up to 28% w/v are possible at ambient temperature. Bronopol is poorly soluble in non-polar solvents but shows a high affinity for polar organic solvents.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.